Recent advances of highly selective CDK4/6 inhibitors in breast cancer

作者
Hanxiao Xu,Shengnan Yu,Qian Liu,Xun Yuan,Sridhar Mani,Richard G. Pestell,Kongming Wu
出处
期刊:Journal of Hematology & Oncology [BioMed Central]
卷期号:10 (1): 97-97 被引量:169
标识
DOI:10.1186/s13045-017-0467-2
摘要

Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which are pivotal drivers of cell proliferation by combination with cyclin D, draw more and more attention. Subsequently, extensive studies were carried out to explore drugs inhibiting CDK4/6 and assess the efficacy and safety of these drugs in cancer, especially breast cancer. Due to the insuperable adverse events and the less activity observed in vivo, the drug development of the initial pan-CDK inhibitor flavopiridol was consequently discontinued, and then highly specific inhibitors were extensively researched and developed, including palbociclib (PD0332991), ribociclib (LEE011), and abemaciclib (LY2835219). Food and Drug Administration has approved palbociclib and ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, and recent clinical trial data suggest that palbociclib significantly improved clinical outcome when combined with letrozole or fulvestrant. Besides, the favorable effects of abemaciclib on prolonging survival of breast cancer patients have also been observed in clinical trials both for single-agent and combination strategy. In this review, we outline the preclinical and clinical advancement of these three orally bioavailable and highly selective CDK4/6 inhibitors in breast cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
思源的应助被科研通管家采纳,获得10
刚刚
田様的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
刚刚
领导范儿的应助被科研通管家采纳,获得10
刚刚
刚刚
1秒前
guoguozhijia158完成签到,获得积分10
1秒前
丘比特的应助被科研通管家采纳,获得10
1秒前
秋风的应助被科研通管家采纳,获得20
1秒前
尺八发布了新的文献求助10
1秒前
在水一方的应助被科研通管家采纳,获得10
1秒前
华仔的应助被科研通管家采纳,获得10
1秒前
ZX801完成签到,获得积分10
1秒前
FashionBoy的应助被Irene采纳,获得10
1秒前
yy完成签到,获得积分10
1秒前
落后凝莲完成签到,获得积分10
1秒前
爱柠完成签到,获得积分10
2秒前
3秒前
3秒前
Ava的应助被ZX801采纳,获得10
4秒前
4秒前
5秒前
7秒前
忧伤的南莲完成签到,获得积分10
7秒前
111发布了新的文献求助10
7秒前
7秒前
是唐朝越啊完成签到,获得积分10
8秒前
LGL发布了新的文献求助10
8秒前
YAYING发布了新的文献求助10
10秒前
鹿饮溪发布了新的文献求助10
10秒前
王乐乐发布了新的文献求助10
11秒前
zhangyi完成签到 ,获得积分10
11秒前
占曼荷完成签到,获得积分20
11秒前
只只完成签到,获得积分10
11秒前
Taikonaut发布了新的文献求助10
11秒前
jiehe完成签到,获得积分10
12秒前
小蘑菇的应助被lqiu采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578698
关于积分的说明 21861559
捐赠科研通 7791583
什么是DOI,文献DOI怎么找? 3436814
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483582